Victoza liraglutide APPROVED
Drug Profile
ModalityPeptide
RouteSC
Therapy AreaCVRM
Launch2010-01-25
US LOE2023-06-01
Peak Sales Est$4000M
Formulations[{"id":"victoza-sc","doses":"0.6mg, 1.2mg, 1.8mg","route":"SC","device":"FlexPen","setting":"PATIENT
Companies
NVO (ORIGINATOR)100%
Mechanism: GLP-1 receptor agonist
Expert: Glucagon-like peptide-1 receptor agonist that enhances glucose-dependent insulin secretion, suppresses glucagon, delays gastric emptying, and reduces appetite via hypothalamic signaling.
Everyday: Mimics a gut hormone that reduces appetite and helps control blood sugar by signaling fullness to the brain.
Targets: ["GLP-1R"]
Revenue History
PeriodRevenue ($M)
2025$1,100M
Data from Supabase · Updated 2026-03-24